Hepatic safety of ketoconazole in Cushing’s syndrome: results of a Compassionate Use Programme in France

Abstract

These findings highlight the need for close monitoring of liver enzymes especially during the first six months of treatment. Liver enzyme abnormalities usually occurred within four weeks were asymptomatic and could be reversed on timely discontinuation of KTZ.